Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Remus PharmaceuticalsNSE:REMUS +2.21%55 Cash Ratio is 0.37 as of Mar. 2026, which is 68% above its 10-year median of 0.22. GuruFocus rates NSE:REMUS with a GF Score™ of 55/100 and a GF Value™ of ₹2,071.36 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 119 Medical Distribution companies, Remus Pharmaceuticals ranks better than 73.11% on this metric.
Remus Pharmaceuticals has a Cash Ratio of 0.37. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Remus Pharmaceuticals's Cash Ratio or its related term are showing as below:
NSE:REMUS'
s Cash Ratio Range Over the Past 10 Years
Min: 0.11 Med: 0.22 Max: 0.41
Current: 0.37
During the past 7 years, Remus Pharmaceuticals's highest Cash Ratio was 0.41. The lowest was 0.11. And the median was 0.22.
NSE:REMUS's Cash Ratio is ranked better than 73.11% of 119
companies
in the Medical Distribution industry
Industry Median: 0.19
vs NSE:REMUS: 0.37
Remus Pharmaceuticals (NSE:REMUS) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Remus Pharmaceuticals's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Remus Pharmaceuticals Cash Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Remus Pharmaceuticals's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Remus Pharmaceuticals's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Remus Pharmaceuticals (NSE:REMUS) has a Cash Ratio of 0.37 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Remus Pharmaceuticals and its competitors. This is 68% above median its historical median of 0.22. Over the past decade, Remus Pharmaceuticals' Cash Ratio has ranged from 0.11 to 0.41. According to the industry distribution chart, Remus Pharmaceuticals ranks #32 out of 119 companies in the Medical Distribution industry, placing it in the top 26.9%.
Is Remus Pharmaceuticals' Cash Ratio too high?
Remus Pharmaceuticals' current Cash Ratio of 0.37 is 68% above median its 10-year median of 0.22. Over the past 10 years, this metric has ranged from a low of 0.11 to a high of 0.41. The Medical Distribution industry median Cash Ratio is 0.19. Remus Pharmaceuticals' value of 0.37 is 94.7% above this industry median. Based on the distribution chart, Remus Pharmaceuticals ranks #32 out of 119 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Remus Pharmaceuticals has a GF Score™ of 55/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Remus Pharmaceuticals' Cash Ratio compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Remus Pharmaceuticals ranks #32 out of 119 companies for Cash Ratio. This puts Remus Pharmaceuticals in the upper half of its industry. The industry median Cash Ratio is 0.19. Remus Pharmaceuticals' value of 0.37 is 94.7% above this benchmark. Historically, Remus Pharmaceuticals' own Cash Ratio has ranged from 0.11 to 0.41 over the past decade. While the company's 10-year median is 0.22 vs. the industry median of 0.19, Remus Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Distribution company?
The median Cash Ratio among Medical Distribution companies is 0.19, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Remus Pharmaceuticals's current Cash Ratio of 0.37 is 94.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Remus Pharmaceuticals and its competitors. For the Medical Distribution industry, the median Cash Ratio is 0.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Remus Pharmaceuticals's current Cash Ratio is 0.37, which is 68% above median its own 10-year median of 0.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Remus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Remus Pharmaceuticals (NSE:REMUS) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹2,071.36, compared to a current price of ₹910.15 — trading 56.1% below its estimated fair value. The current Cash Ratio is 0.37, which is 68% above median its 10-year median of 0.22 and 94.7% above the Medical Distribution industry median of 0.19. Remus Pharmaceuticals' overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Remus Pharmaceuticals (NSE:REMUS), the current Cash Ratio is 0.37 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Remus Pharmaceuticals (NSE:REMUS) Overvalued in 2026?
Based on GuruFocus' analysis, Remus Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹910.15 is trading 56.1% below its estimated GF Value™ of ₹2,071.36.
GuruFocus considers Remus Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for NSE:REMUS:
Cash Ratio: 0.37 (68% above median its 10-year median of 0.22)
GF Value™: ₹2,071.36 vs. price of ₹910.15 (56.1% below fair value)
Industry Position: 94.7% above the Medical Distribution median (#32 of 119)
No single metric tells the full story. See the NSE:REMUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Remus Pharmaceuticals Ltd is engaged in the marketing & distribution of finished formulations of pharmaceutical drugs. The company also deals in API (Active Pharmaceutical Ingredient). It also provides technical consultancy services to various distributors for the preparation of reports on the dossiers of the products to be registered by them in various countries. Remus Pharmaceuticals market niche medicinal combinations. It exports generic drugs by conducting intensive market research in the pharmaceutical industry to expand its product portfolio.
55GF Score
Get the complete analysis for NSE:REMUS
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:REMUS has been successfully added to your 
